ArticleThe Journal of experimental medicine2021
CD4+ T cells in the lungs of acute sarcoidosis patients recognize an Aspergillus nidulans epitope.
Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Metabolomic signaling in sarcoidosis pathogenesis.Current opinion in immunology · 2026Review
- Exploring microbial signatures in sarcoidosis: etiological and therapeutic implications of host-microbiota interactions.Frontiers in immunology · 2026Review
- Whole genome sequencing of the pulmonary microbiome in interstitial lung disease subtypes.Respiratory research · 2025Article
- Residential fungal β-(1,3)-D-glucan exposure is associated with decreased pulmonary function in fibrotic pulmonary sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Occupational exposures in sarcoidosis: a protocol for a multicentre regional case-control study in the UK.BMJ open respiratory research · 2025Article
- Microbiome Against the Background of the Complex Aetiology in Sarcoidosis-What Do We Already Know?Life (Basel, Switzerland) · 2025Review
- A framework for exclusion of alternative diagnoses in sarcoidosis.Journal of autoimmunity · 2024Review
- Infectious and non-infectious precipitants of sarcoidosis.Journal of autoimmunity · 2024Review
- In Silico Identification of Peanut Peptides Suitable for Allergy Immunotherapy in HLA-DRB1*03:01-Restricted Patients.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Renin-Angiotensin-Aldosterone System: A Potential Source of Biomarkers and Therapeutic Targets for Sarcoidosis.American journal of respiratory and critical care medicine · 2024Article
- Review
- Secrets and lies of host-microbial interactions: MHC restriction and trans-regulation of T cell trafficking conceal the role of microbial agents on the edge between health and multifactorial/complex diseases.Cellular and molecular life sciences : CMLS · 2024Review
- How to Predict Binding Specificity and Ligands for New MHC-II Alleles with MixMHC2pred.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Bridging the Gap between Innate and Adaptive Immunity in the Lung: Summary of the Aspen Lung Conference 2022.American journal of respiratory cell and molecular biology · 2023Article
- Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation.Immunity · 2023Article
- The MHC Motif Atlas: a database of MHC binding specificities and ligands.Nucleic acids research · 2023Article
- Genetic and geographic influence on phenotypic variation in European sarcoidosis patients.Frontiers in medicine · 2023Article
- Differential diagnosis of pulmonary sarcoidosis: a review.Frontiers in medicine · 2023Review
- Pentraxin 3 Inhibits Complement-driven Macrophage Activation to Restrain Granuloma Formation in Sarcoidosis.American journal of respiratory and critical care medicine · 2022Article
- The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis.Microbiome · 2022Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
Löfgren's syndrome (LS) is an acute form of sarcoidosis characterized by a genetic association with HLA-DRB1*03 (HLA-DR3) and an accumulation of CD4+ T cells of unknown specificity in the bronchoalveolar lavage (BAL). Here, we screened related LS-specific TCRs for antigen specificity and identified a peptide derived from NAD-dependent histone deacetylase hst4 (NDPD) of Aspergillus nidulans that stimulated these CD4+ T cells in an HLA-DR3-restricted manner. Using ELISPOT analysis, a greater number of IFN-γ- and IL-2-secreting T cells in the BAL of DR3+ LS subjects compared with DR3+ control subjects was observed in response to the NDPD peptide. Finally, increased IgG antibody responses to A. nidulans NDPD were detected in the serum of DR3+ LS subjects. Thus, our findings identify a ligand for CD4+ T cells derived from the lungs of LS patients and suggest a role of A. nidulans in the etiology of LS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.